Home / Guides by goal / Longevity
Best Peptides for Longevity: What the Evidence Shows
Do epitalon, MOTS-c or GHK-Cu extend lifespan? What human evidence exists (little), what comes only from mice, and where HHS and FDA disagree.
The short answer
No peptide we reviewed has evidence that it extends lifespan or slows aging in people, so we cannot name a “best.” That is the finding. The three peptides most often marketed for longevity, epitalon, MOTS-c and GHK-Cu, rest on mice, lab work and mechanism, plus a few small human studies of epitalon that did not test aging or lifespan, and one small skin trial that found no objective benefit (GHK-Cu). None is FDA-approved.
If a source tells you one of these peptides “extends lifespan,” “reverses aging” or “repairs telomeres,” it is going beyond the evidence.
On this page
Longevity is where peptide marketing runs furthest ahead of the research. We looked for any peptide that has been shown to extend human life or slow aging. We did not find one, and this guide explains why.
The ranking, by strength of evidence
| Peptide | U.S. status | Strongest evidence |
|---|---|---|
| 1. Epitalon | Limited human data | |
| 2. GHK-Cu | Limited human data | |
| 3. MOTS-c | Animal studies |
How do we decide what is “best”?
“Best” means best evidence, not best marketing. For longevity, strong evidence would look like this:
- Randomized, controlled trials in people that follow a clinically meaningful outcome (illness, function, survival) over a long time, not only a lab marker.
- Published, peer-reviewed results and a regulator’s review of safety.
- A known safety profile over the length of use being proposed.
None of the three peptides gets to step 1. We therefore do not rank them for effectiveness. The table below shows only how far each one’s evidence reaches, from the furthest to the least far. It is not a recommendation.
| GHK-Cu | Epitalon | MOTS-c | |
|---|---|---|---|
| FDA-approved | No | No | No |
| Controlled human trial | One small trial in skin care after laser resurfacing: no objective improvement. Older wound-healing trials are not about aging | None on a clinical outcome | None; FDA found no human studies |
| Limited human data | — | A marker study in 40 women that did not measure sleep or aging; a study of clock genes in night-shift workers; injections near the eye in retinitis pigmentosa; an abstract with no details | None |
| Animal data | A rat model of a ligament repair; transient improvement | Mice: fewer tumors and longer life, as described by FDA | Mice and a rat model: metabolic and vascular findings; bone-cell effects in lab work |
| Lab and mechanism | Collagen production in cells | Telomerase and telomere lengthening in vitro | Rapid breakdown in human blood, in vitro |
| Where the evidence reaches | Human trial, no benefit shown | Small human studies, none on aging or lifespan | Animal only |
Sources: FDA on epitalon and MOTS-c, Miller 2006 and a rat study of GHK-Cu.
We have not reviewed other peptides promoted for longevity, such as thymosin alpha-1. This guide will be updated when we have.
What does the evidence say about epitalon?
Epitalon is not FDA-approved for any use.
- Human trials with clinical outcomes: FDA identified none. Its review looked at epitalon for insomnia, the only use it evaluated; it did not evaluate longevity.
- The human marker study: Ivko 2021 gave epitalon under the tongue for 20 days to healthy women aged 40 to 50 working night shifts (20 received it, 20 did not). A urinary metabolite of melatonin rose. The study did not measure sleep, the blinding is unclear, and it reported no safety data (FDA presentations).
- Two other human studies: FDA’s briefing also lists a sublingual study of circadian genes in night-shift workers (Khavinson 2021) and injections near the eye in people with retinitis pigmentosa (Khavinson 2002b). Neither tested aging or lifespan.
- An older abstract: Korkushko 2007, FDA says, said pineal-gland preparations, epitalon and epithalamin, have “no side effects” in older adults, without the route, dose, duration or number of participants.
- Mice: research from 2001 to 2003, as described by FDA, found that mice given intermittent epitalon had fewer or smaller spontaneous tumors and lived longer. Results in mice do not transfer reliably to people.
- Lab studies and mechanism: FDA describes epitalon as increasing telomerase and lengthening telomeres in lab experiments. How that relates to sleep, or to human aging, is unknown.
We read these studies through FDA’s description, not the originals.
Is there a safety concern?
FDA concluded that “there are no clinical data to support the safety of epitalon” in humans. It also raised a theoretical concern linked to the very mechanism being marketed: chronic continuous exposure, by upregulating telomerase and extending telomeres, “could result in carcinogenicity.” That is a theoretical concern: it has not been observed in humans, and it has not been ruled out. FDA also flagged a potential for immune reactions with subcutaneous use, amplified by clumping and impurities.
What does the evidence say about MOTS-c?
MOTS-c is not FDA-approved for any use.
- Human studies: FDA identified none, and no data on human exposure by any route, and no human pharmacokinetic data (FDA presentations; briefing).
- The trial HHS cites: HHS’s policy refers to a randomized trial of “a MOTS-c analogue” with no serious adverse events. An analogue is a different molecule, not MOTS-c. HHS does not identify it in the text we read, and we could not locate it.
- Animals: FDA reports that mice showed less diet-induced obesity and less insulin resistance, a rat model showed less vascular calcification, and other rodent and lab work showed effects on bone cells. FDA described these as small models without dose-response relationships.
- Lab studies: in human blood, MOTS-c breaks down quickly into shorter peptides. FDA says it remains to be determined whether giving MOTS-c to people can produce active concentrations, and the molecular targets are unknown.
- Safety: FDA notes missing clinical and non-clinical safety information, no toxicity studies it could identify, and a concern about immune reactions to an injected 16-amino-acid peptide.
Claims such as “exercise in a bottle” come from rodent data. No human has been shown to get the benefit.
What does the evidence say about GHK-Cu?
GHK-Cu is not an FDA-approved drug. The one randomized skin trial we could read tested GHK-Cu skin care after laser resurfacing in the 13 people who completed it and found no objective difference in redness, wrinkles or skin quality, though participants reported more satisfaction. We found no controlled human trial of GHK-Cu for aging more broadly.
Its status depends on the form: non-injectable GHK-Cu is on FDA’s Category 1 list (substances under evaluation), while FDA flags a risk of immune reactions and limited human data for injectable forms. Category 1 is not approval. FDA says it intends to consult its advisory committee before the end of February 2027. GHK-Cu is not covered by HHS’s Oct. 30 policy.
Where do HHS and FDA disagree?
On Oct. 30, 2026, HHS published an interim policy saying it does not intend to take enforcement action against certain pharmacy compounding of epitalon acetate (subcutaneous or intramuscular, in intermittent courses) and MOTS-c acetate (subcutaneous or intramuscular), under conditions, including a single active ingredient and a patient-specific prescription. It is open to public comment and is not FDA approval. FDA’s drug center had proposed not adding either peptide to the compounding list, and FDA’s advisory committee voted in favor of listing epitalon (7–4–1) and MOTS-c (7–5–2), according to a law-firm account (secondary source).
HHS and FDA reach different conclusions. We present both and do not choose:
| Question | HHS (Appendix B) | FDA (documents above) |
|---|---|---|
| Epitalon safety | CDER’s concerns are “mechanistic rather than based on observed harm”; a controlled human exposure “reported no side effects” | No human safety data; the cited study did not report safety |
| Epitalon routes | Covers subcutaneous and intramuscular | Found no studies by the subcutaneous route |
| MOTS-c safety | “The available safety evidence points in one direction,” citing an analogue trial and rodent studies | No human data with MOTS-c itself |
| Historical use | “Documented and quantified” | Could not be characterized; the data are not published in the text we read |
Both statements can be true at once: no harm observed is not proof of safety, and the policy is about enforcement, not about whether the peptides work.
What about sport?
For MOTS-c, FDA says it is listed as prohibited in Global DRO, the database athletes use to check medications. Check your anti-doping organization for epitalon and GHK-Cu.
Which claims are not supported?
- “Extends lifespan.” Only mice, as described by FDA.
- “Repairs or lengthens telomeres, so it’s safe and good.” FDA sees telomere lengthening as a potential cancer risk. It is a theoretical concern.
- “Improves sleep.” The epitalon study FDA examined for sleep did not measure sleep.
- “Exercise in a bottle.” Rodent data only.
- “There is a human trial of MOTS-c.” The one HHS cites tested an analogue.
- “HHS approved it.” HHS expressed an interim enforcement position, not an approval.
What should you ask a clinician?
- Is there a specific condition behind my interest in longevity (sleep, metabolism, bone health) that has evidence-based treatments?
- Which health measures, such as blood pressure, blood sugar, lipids, fitness and screening, are worth tracking, and what does the evidence say about improving them?
- If a peptide is suggested, what human evidence supports it for my goal, who prepares it, and what are the risks?
We do not give doses, cycles or preparation instructions, and we do not recommend sellers.
Frequently asked questions
Is there a peptide that extends life?
Not that we could find. The peptides most promoted for longevity have not been shown to extend life or slow aging in people.
Is epitalon safe?
FDA said there is no clinical data to support its safety, and it raised a theoretical cancer concern linked to telomere lengthening.
Does MOTS-c work like exercise?
That idea comes from mice and rats. FDA found no human studies of MOTS-c.
Are epitalon and MOTS-c legal now?
Neither is FDA-approved. On Oct. 30, 2026, HHS said it does not intend to take enforcement action against certain compounding of both, under conditions, on an interim basis. That is not an approval or a legalization.
How did we rank them?
We rank by the type of evidence first, then its quality and its result. If no peptide has good evidence for a goal, we say so.
- Human trialsControlled trials in people, published in a journal, that tested a clinical outcome and showed a benefit. The strongest kind of evidence we report.
- Limited human dataSmall, short or inconclusive human studies, including observational studies, uncontrolled trials and controlled trials that did not show a clinical benefit.
- Animal studiesResults in animals often don’t carry over to people.
- Lab studiesCells or tissue in a dish. An early signal, not an answer.
Sources we checked
- FDA presentations to the Pharmacy Compounding Advisory Committee on epitalon (July 24, 2026)FDA. Accessed .
- FDA briefing document on epitalonFDA. Accessed .
- FDA presentations to the Pharmacy Compounding Advisory Committee on MOTS-c (July 23, 2026)FDA. Accessed .
- FDA briefing document on MOTS-cFDA. Accessed .
- GHK-Cu in a rat ACL reconstruction model (PubMed)PubMed. Accessed .
- Federal Register: HHS enforcement discretion policy on 503A peptide compounding (Oct. 30, 2026)Other. Accessed .
- HHS policy, Appendix BOther. Accessed .
- McDermott+: PCAC votes on peptides (secondary source)Other. Accessed .
- FDA 503A Category 1 list (updated May 14, 2026)FDA. Accessed .
- FDA: bulk drug substances that may present significant safety risksFDA. Accessed .
- Miller 2006: GHK-Cu skin care after CO2 laser resurfacing (PubMed)PubMed. Accessed .
- Peptide Supplements and Their Therapeutic Applications in Sports Medicine, Am J Sports Med 2026 (PubMed)PubMed. Accessed .
Written and maintained by the Best Peptides For Editorial Team. How we rate evidence.